Real‐world treatment burden of brentuximab vedotin‐based front‐line regimens in young adults and adults with advanced‐stage classical Hodgkin lymphoma

Real-world treatment burden of brentuximab vedotin-based frontline regimens in young adults and adults with advanced-stage classical Hodgkin lymphomaTo the Editor, We read with great enthusiasm the multicentre, retrospective study by Porges et al. in British Journal of Haematology in August 2026, 1 assessing front-line brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) in 100 advanced-stage classical Hodgkin lymphoma (cHL) patients (median age, 30 years).The outstanding disease control reported by the

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-11-18
DOI
https://doi.org/10.1111/bjh.70951
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real‐world treatment burden of brentuximab vedotin‐based front‐line regimens in young adults and adults with advanced‐stage classical Hodgkin lymphoma

Annamaria Vincenzi, Sara Pellegrino, Claudia Giordano, Fabrizio Pane et al.
British Journal of Haematology
Lymphoma Diagnosis and Treatment
article

Real‐world treatment burden of brentuximab vedotin‐based front‐line regimens in young adults and adults with advanced‐stage classical Hodgkin lymphoma

Annamaria Vincenzi, Sara Pellegrino, Claudia Giordano, Fabrizio Pane, Marco Picardi, Novella Pugliese
article en

Abstract

Real-world treatment burden of brentuximab vedotin-based frontline regimens in young adults and adults with advanced-stage classical Hodgkin lymphomaTo the Editor, We read with great enthusiasm the multicentre, retrospective study by Porges et al. in British Journal of Haematology in August 2026, 1 assessing front-line brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) in 100 advanced-stage classical Hodgkin lymphoma (cHL) patients (median age, 30 years).The outstanding disease control reported by the

British Journal of Haematology
Federico II University Hospital (IT), University of Naples Federico II (IT)
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon